Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 9620 Medical Center Drive, Suite 300 BEIJING BEJ 100025 |
Tel: | N/A |
Website: | www.casipharmaceuticals.com |
IR: | See website |
Key People | ||
Wei-Wu He Chairman of the Board, Chief Executive Officer | Wei Zhang President, Principal Financial Officer | Chunhua Wang Chief Operating Officer |
Huang Hai Global Chief Commercial Officer, Executive Vice President, General Manager of Casi China | Alexander A. Zukiwski Executive Vice President, Chief Medical Officer | Kun Qian Vice President, Controller |
Wei Gao General Counsel | Fuqiang Zhang Chief Commercial Officer |
Business Overview |
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company's Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets. |
Financial Overview |
For the nine months ended 30 September 2023, CASI Pharmaceuticals Inc revenues decreased 3% to $27M. Net loss applicable to common stockholders decreased 3% to $20.9M. Revenues reflect Lease income from a related party decrease from $60K to $0K. Lower net loss reflects Other income increase from $60K to $1.9M (income), Change in fair value of investment in eq decrease of 47% to $1.1M (expense), Interest (income) expense. |
Employees: | 224 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $26.74M as of Dec 31, 2023 |
Annual revenue (TTM): | $42.26M as of Dec 31, 2023 |
EBITDA (TTM): | -$26.03M as of Dec 31, 2023 |
Net annual income (TTM): | -$40.42M as of Dec 31, 2023 |
Free cash flow (TTM): | N/A |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 13,321,507 as of Sep 30, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |